Neil Hunt, chief executive, Alzheimer’s Society
Although the first High Court judicial review of the National Institute for Clinical Excellence’s decision processes on drugs for Alzheimer’s Disease did not reject its guidance, it did find that it was discriminatory. One-nil to the Alzheimer’s Society. Subsequently, the Commons health select committee said NICE needed to reconsider how it made decisions and the Court of Appeal ruled that the body must make its economic model publicly available.
Mr Hunt has also played a key role in developing England’s first national dementia strategy. He has previously worked for the NSPCC, the Home Office and the Department of Education and Skills.